Bayer Corp. and Janssen Pharmaceuticals Inc. seem to have the best defense against product liability suits claiming they did not provide adequate warning that Xarelto (rivaroxaban) increases the risk of bleeding: labeling that repeatedly specifies the risk.
In the fifth case to go to trial, Russell v. Janssen, jurors in a state court case in Philadelphia issued...





